Cefprozil versus cefaclor in the treatment of acute and uncomplicated urinary tract infections. Cefprozil Multicenter Study Group.

Abstract

Cefprozil is a new oral cephalosporin with an in vitro spectrum of activity that includes the pathogens most commonly associated with acute and uncomplicated urinary tract infections (UTIs). A multicenter, randomized study was conducted to compare the clinical efficacy and safety of cefprozil, administered once daily, with cefaclor, administered three times a day, for ten days in patients 2 years of age or older who had acute and uncomplicated UTIs. The rate of satisfactory clinical response in evaluable patients was 87% in the cefprozil group and 84% in the cefaclor group. The patient bacteriologic response rates were also similar: 83% for cefprozil and 85% for cefaclor. The overall effective response rate for both cefprozil and cefaclor was 77%. Both drugs were well tolerated, with no difference in the incidence of drug-related adverse events. Because of its efficacy and once-daily dosing regimen, cefprozil may be an alternative to currently available oral antibiotics in the treatment of UTIs.

• Authors: A Iravani, C A Doyle, S J Durham, R B Wilber
• Journal: Clinical therapeutics (Clin Ther) 1992 Mar-Apr Vol. 14 Issue 2 Pg. 314-26 ISSN: 0149-2918 [Print] United States
• PMID: 1611652 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Cephalosporins
• cefprozil
• Cefaclor

Topics

• Acute Disease
• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Bacterial Infections (drug therapy)
• Cefaclor (adverse effects, therapeutic use)
• Cephalosporins (adverse effects, therapeutic use)
• Child, Preschool
• Colony Count, Microbial
• Drug Administration Schedule
• Female
• Humans
• Male
• Middle Aged
• Urinary Tract Infections (drug therapy)